<DOC>
	<DOCNO>NCT01311232</DOCNO>
	<brief_summary>This study retrospective analysis identify factor influence hepatitis B virus reactivation patient treat rituximab contain chemotherapy . Rituximab monoclonal antibody target CD20 induces B-cell depletion result prolong immune suppression . This lead frequent reactivation patient previous history exposure HBV HBV carrier . We collect clinical feature laboratory finding patient satisfied inclusion criterion follow . 1 . Patients diagnose diffuse large B-cell lymphoma ( DLBCL ) \ follicular B-cell lymphoma ( FL ) . 2 . Patients receive least two cycle rituximab-CHOP rituximab-CVP primary treatment 3 . Patients history previous exposure HBV - HBV surface antigen ( HBs Ag ) positive Or - HBV core antibody ( IgG anti-HBc antibody ) positive Then , compare HBV reactivation group control group ( HBV reactivation happen ) find factor influence HBV reactivation .</brief_summary>
	<brief_title>Factors Influencing Hepatitis B Virus Reactivation Lymphoma Patients Treated With Rituximab</brief_title>
	<detailed_description>Description factor associate Hepatitis B virus reactivation : - Laboratory parameter define HBV status/activity time treatment initiation - Lymphoma stage rituximab treatment initiation ( Ann Arbor , B-symptoms , bone marrow involvement , IPI , ECOG-score , LDH ) - Immunochemotherapy regimen ( treatment line , rituximab dose cycle ) - Disease status time HBV reactivation - Antiviral prophylaxis ( medication , dose , duration time time reactivation ) - Patient demographic ( age , gender , residence , ethnic origin , smoke status , alcohol consumption occupation ) Time Hepatitis B virus reactivation - The time start rituximab-containing immunochemotherapy first evidence HBV reactivation meeting criterion - Description prophylaxis treatment antiviral medication HBV vaccination Time initiation antiviral therapy prophylaxis relate clinical laboratory sign possible HBV reactivation Anti-viral medication use prophylaxis therapy - Description outcomes Outcomes HBV reactivation Outcomes rituximab-containing immunochemotherapy Demographics previous infection history : Age , gender , nationality , race , social history , past medical history - Parameters associate lymphoma : Ann Arbor stage , number extranodal involvement , serum LDH , serum β2-microglobulin , ECOG performance status , presence B symptom , International Prognostic Index , bone marrow invasion - Laboratory parameter associate hepatitis B virus : hepatitis B surface antigen ( HBsAg ) , hepatitis B surface antibody ( anti- HBs ) , hepatitis B e antigen ( HBeAg ) , hepatitis B core antibody ( anti-HBc ) , hepatitis B e antibody ( anti-HBe ) , serum HBV DNA - Lymphoma treatment history : Line treatment ( first line , second line ) , rituximab chemotherapy administration ( dose , schedule ) , start date , last treatment date - Prophylaxis treatment HBV reactivation : antiviral drug ( dose , schedule , duration ) - Hepatitis B virus reactivation : onset , serologic marker , outcome</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Inclusion Criteria 1 . Patients diagnose diffuse large Bcell lymphoma ( DLBCL ) follicular Bcell lymphoma ( FL ) . 2 . Patients receive least two cycle rituximabCHOP rituximabCVP primary treatment 3 . Patients history previous exposure HBV HBV surface antigen ( HBs Ag ) positive Or HBV core antibody ( IgG antiHBc antibody ) positive 4 . Patients document HBV reactivation ( definite presumptive ) occur treatment ( least two cycle RCHOP RCVP ) within 12 month last dose rituximab Definitive HBV reactivation Elevation serum HBV DNA level &gt; 1 log IU/mL baseline absolute increase HBV DNA 6 log10 IU/mL HBsAg positive patient Presumptive HBV reactivation Increase ALT ( ≥3x baseline value absolute value ≥100 U/L ) positive conversion HBs Ag previously HBsAgnegative patient 1 . Patients receive chemotherapy RCHOP RCVP diagnosis 2. patient diagnosed HIV , HCV HDV coinfection 3 . Patients undergone allogenic stem cell transplantation hepatitis B virus reactivation document</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>rituximab , lymphoma , hepatitis B virus</keyword>
</DOC>